Tumor News and Research

RSS

Salk scientists find new immunotherapy treatment for glioblastoma

Glioblastoma, the most common and deadly form of brain cancer, grows rapidly to invade and destroy healthy brain tissue. The tumor sends out cancerous tendrils into the brain that make surgical tumor removal extremely difficult or impossible.

11 Aug 2023

New gene therapy shows promise for treating fusion-driven cancers

A new study presents a promising treatment method for so-called fusion-driven cancers, which are currently often difficult to cure. These fusion-driven cancers are caused by an error in cell division that creates a fusion of different genes.

11 Aug 2023

New Alzheimer’s drug raises hopes — along with questions

The FDA has approved Leqembi, the first disease-modifying treatment for early-stage Alzheimer's and a precursor condition, mild cognitive impairment.

11 Aug 2023

Gut microbiota could affect the responsiveness and efficacy of cancer treatment

A vast number of microbes colonizes the human body to form an ecological community known as the microbiota. Microbiota are made up of bacteria, viruses, fungi, and archaea.

11 Aug 2023

Study explores the use of existing medicines to revolutionize cancer treatment

In a recent study published in the journal of Genes & Diseases, Research team led by Lu explores the potential for the use of FDA-approved hypertension and EMA-approved cough medicines to revolutionize cancer treatment.

10 Aug 2023

A drug for heart conditions improves efficacy of melanoma therapies

A collaborative study undertaken by the Navarrabiomed Biomedical Research Center (Pamplona, Navarre), the Institute of Neurosciences CSIC-UMH (Sant Joan d'Alacant, Valencian Community) and IRB Barcelona (Barcelona, Catalonia) shows that the administration of ranolazine, a drug currently used to treat heart conditions, improves the efficacy of current therapies for melanoma, in mouse models of this disease.

10 Aug 2023

Ovarian cancer patients enrolled in first-in-human trial of CAR T cell therapy

Recently published preclinical data by City of Hope scientists shows the immunotherapy is effective. Advanced ovarian cancer patients are now being enrolled in a Phase 1 first-in-human trial.

10 Aug 2023

New gene-editing tool helps to study single-base mutations in cancer

A change in just one letter in the code that makes up a cancer-causing gene can significantly affect how aggressive a tumor is or how well a patient with cancer responds to a particular therapy.

10 Aug 2023

Automated cell analysis with Haemorasis can help diagnose blood disorders

Scientists from the German Cancer Research Center (DKFZ) and the Cambridge Stem Cell Institute have developed an AI system that recognizes and characterizes white and red blood cells in microscopic images of blood samples.

10 Aug 2023

Tumor's consistency can have a decisive influence on cancer progression

Doctors have been palpating suspicious hardened areas under their patients' skin throughout recorded history.

10 Aug 2023

How does sun exposure affect skin microbiota composition and diversity?

Researchers recruited healthy volunteers to study how ultraviolet radiation exposure impacted their skin microbiota composition, diversity, and overall skin health.

10 Aug 2023

Study explores the diverse expression patterns of T cell priming markers across cancers

A recent study explored transcriptomics of T-cell priming markers (TPMs) across different cancers.

10 Aug 2023

How conversion between different types of cell death contributes to disease

Researchers elucidate the role of cell death in the pathogenesis of different diseases.

10 Aug 2023

MaxCyte signs strategic platform license with Lyell Immunopharma

From MaxCyte, Inc. 10 Aug 2023

MaxCyte and Vittoria Biotherapeutics sign strategic platform license to advance next generation cellular therapies

MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, and Vittoria Biotherapeutics (Vittoria), a leading edge, gene-edited cell therapeutics company with novel platform technologies poised to develop a pipeline of highly differentiated cellular therapies for both oncology and immunology indications, today announced the signing of a strategic platform license (SPL) of MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to Vittoria Biotherapeutics.

From MaxCyte, Inc. 10 Aug 2023

GABA transfer between skin cells promotes melanoma initiation

The transfer of a neurotransmitter from one type of skin cell to another (melanocytes to keratinocytes) altered electrical activity and promoted melanoma initiation in preclinical models, according to results published in Cancer Discovery, a journal of the American Association for Cancer Research.

9 Aug 2023